Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, announced its support for final recommendations from Australia’s Therapeutic Goods Administration (TGA) regarding the Authorized Prescriber scheme for psilocybin and MDMA. The updated framework expands eligible therapy teams and treatment settings beyond hospital environments, facilitating the scaling of psychedelic-assisted therapy across Australia.
Under the revised rules, authorized psychiatrists can prescribe Optimi’s GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression. The company stated that the changes could accelerate adoption by increasing workforce capacity, particularly in rural and regional areas, while broadening reimbursement opportunities across both public and private payers.
Optimi also highlighted that no serious adverse events have been reported under Australia’s regulated commercial psychedelic treatment program since December 2025, supporting continued expansion of what the company describes as the world’s most advanced commercial market for prescribed psilocybin and MDMA therapies.
The implications for the industry are significant. Australia’s regulatory evolution positions the country as a global leader in psychedelic-assisted therapy, potentially setting a precedent for other nations. For patients, the updated framework means greater access to treatments for PTSD and treatment-resistant depression, especially in underserved areas. For Optimi, it opens up a larger addressable market and reinforces its role as a key supplier of GMP-certified psychedelics.
The TGA’s move also signals growing acceptance of psychedelic therapies within mainstream medicine, which could encourage further research and investment. As reimbursement pathways improve, the economic burden of mental health conditions may be reduced through more effective treatments. However, the long-term impact will depend on continued safety monitoring and integration into healthcare systems.
Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies. For more information, visit https://www.optimi.net/.
